Chair succession and addition of US-based industry expertise

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces the following changes to the Board of Directors.

Further to the AGM Statement & Succession Planning announcement in June 2023, which set out the Company’s plan to evolve its Board of Directors as it enters a new phase of commercial growth, Creo announces the appointment of Kevin Crofton and Brent Boucher as independent Non-Executive Directors. Both Kevin and Brent are expected to join the Board with effect from 1 July 2024, with Kevin succeeding Charles Spicer as Chair.

Charles has led the Board since the Company’s IPO in December 2016 and has overseen an outstanding period of change and transformation. During this time, the Group has evolved from a UK pre-market, pre-revenue early-stage medical device innovator, into an international commercial group with a range of proprietary innovative surgical solutions delivering outstanding clinical outcomes and health economic benefits and a pipeline of post-market clinical programmes with globally recognised partners.

Kevin Crofton is an accomplished business leader with over three decades of extensive international experience in the technology industry. He has a successful track record of driving innovation and generating profitable growth. Most recently, Kevin was the CEO of Comet Holdings AG, a Swiss listed technology company, where he delivered significant shareholder value by driving greater customer engagement. Prior to this, he was CEO of SPTS Technologies where he led the PE backed management buyout and exit of the company to Orbotech, Inc., joining the team who subsequently sold the group to KLA-Tencor Corporation for $3.4bn. Kevin has also acted as Chairman of SEMI International and the UK Compound Semiconductor Applications Catapult.

Brent Boucher brings extensive experience in the commercialisation of novel medical devices and has a record of success in growing and transforming businesses across a range of medical device specialities, including technologies, oncology interventions, surgical solutions and respiratory care. Brent is recognised as a business leader of multiple innovative growth businesses focused on commercial optimisation, new product, technology and procedural introductions, global market entry and strategic M&A. Throughout his career in the USA, Brent has held a number of executive positions in large multinational Medtech companies, including Covidien (acquired by Medtronic), AngioDynamics and Nuvasive, working to successfully deliver revenue growth and shareholder value.

Craig Gulliford, Chief Executive Officer of Creo, said:

“On behalf of the Board, I would like to thank Charles for his enormous contribution to Creo over the past eight years as Chair. He has led the Board as we transitioned from a privately held MedTech startup, with big ambition, through IPO and subsequent funding rounds, into what is now an internationally commercialised public company with significant global partners. His guidance during this period of growth and evolution from both a personal and business perspective has been invaluable. Charles leaves Creo extremely well positioned for commercial expansion as we move into a significant period of growth. We thank him again for everything he has helped us to achieve.

“We are delighted to appoint Non-Executive Directors of the calibre of Kevin and Brent. They are stalwart international executives, bringing with them deep industry knowledge as well as proven strategic capabilities and senior commercial execution experience. It has been a pleasure to get to know both Kevin and Brent over the last few months as we have worked through the selection process and begun to immerse them into the team and the business. I look forward to working with them on the next stage of Creo’s journey.”

Charles Spicer, Chair of Creo, said:

“It has been a privilege to serve as Creo’s Chair and work alongside my fellow directors and our dedicated staff since our IPO in 2016. I applaud and thank all the Creo team for their success in commercialising minimally invasive electrosurgical devices in both endoscopy and with surgical robotics partners internationally through Creo’s Kamaptive licensing programme. Thanks also are due to all our fellow shareholders for their patient support through challenging markets and to our dedicated advisers for their wise counsel along the way. I welcome Kevin and Brent, with their invaluable skillsets and experience, to the Board and wish them and Creo the best of luck as they accelerate our clinical and commercial progress around the world.”

Posted 13/05/2024

For press enquiries please contact For all other enquiries please visit our Contact page.

Related News

Further news

15 May 2024

Full results - Final Results Strong revenue growth and significant commercial progress (9th May 2024)


07 May 2024

Creo Medical receives King’s Award for Enterprise in Innovation


02 May 2024

MicroBlate Flex in new clinical trial at Royal Brompton Hospital


24 April 2024

NHS Supply Chain real-world data demonstrates substantial cash savings


19 March 2024

Welsh Labour Leader visits Creo’s facilities


05 February 2024

Strategic Collaboration with Khalifa University of Science and Technology, Abu Dhabi


31 January 2024

Roll-out of Speedboat® UltraSlim reaches Asia Pacific


10 January 2024

First Use of Speedboat® UltraSlim in Latin America


13 December 2023

First European Speedboat® UltraSlim procedure marks early commercial launch


01 November 2023

Speedboat® UltraSlim: US FDA Clearance